# A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

> **NCT06365437** · PHASE2 · TERMINATED · sponsor: **ITB-Med LLC** · enrollment: 33 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **BIOLOGICAL:** TCD601
- **DRUG:** Tacrolimus (TAC)
- **DRUG:** Corticosteroids (CS)
- **DRUG:** Mycophenolate Mofetil (MMF)
- **DRUG:** ATG

## Key facts

- **NCT ID:** NCT06365437
- **Lead sponsor:** ITB-Med LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-06
- **Primary completion:** 2024-12-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** After enrolment was complete, and sufficient data was collected to fully characterize the highest dose cohort, study follow up was terminated by the sponsor for non-safety related reasons.
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365437, "A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06365437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*